Nascent Biotech Inc., a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, and HypoSpray Pharma, a clinical and commercial stage drug delivery technology company, have joined forces to develop an alternative delivery mechanism for patients who can benefit from Pritumumab (PTB), Nascent’s lead monoclonal antibody cancer treatment asset, which is now in Phase II clinical research for the treatment of Brain Cancer.
 
Once successfully commercialized, Nascent hopes to eliminate bi-weekly weekly infusions, allowing patients to administer Pritumumab and avoid inconvenient, tedious, and uncomfortable multi hour cancer center treatment visits.
 
HypoSpray Pharma has developed innovative technology for delivering active ingredients across the skin and mucosa. The company has a Drug Master File of record with the FDA for its delivery system, which enables measured application of a biological peptide to mucosal membranes or intact skin, promoting rapid absorption and bioavailability.
 
Nascent CEO, Sean Carrick, commented: “We couldn’t be more excited to work with HypoSpray’s team and its leading delivery system technology. This collaboration has the potential to drive tangible breakthroughs in cancer treatment and patient care that enable home administration, eventually eliminating the need for bi-weekly multi-hour visits to the infusion center, materially improving quality of life for patients undergoing treatment.”
 
HypoSpray Chairman and co-developer of the HypoSpray technology, Kenneth Kirby, said, “We are optimistic about our ability to enable effective delivery of Pritumumab. We have already successfully demonstrated our ability to accomplish similar objectives with several other peptides, including Melanocortin, Insulin, and Incretins, saving patients precious time and energy avoiding traditional infusion delivery.”